Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a triple laser combo turn back sun damage and ward off skin cancer?

NCT ID NCT07789002

Prevention Sponsor: Merete Haedersdal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This trial tests whether combining three light-based treatments can improve sun-damaged facial skin and possibly help prevent skin cancer. Researchers will treat one side of each participant's face with a thulium laser, an Er:Glass laser, and intense pulsed light, while the other side serves as an untreated comparison. The study includes 35 adults with signs of facial photodamage, such as actinic keratoses, age spots, and rough texture. Participants are followed for 14 months to see how the skin looks and how gene activity in the skin changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of three light-based treatments: 1927-nm thulium laser, 1550-nm Er:Glass laser, and intense pulsed light (IPL), applied to one side of the face.
What this could lead to
If it works, this could point toward a more effective way to treat sun-damaged skin and potentially lower the risk of skin cancer.
What could go wrong
This is a small, early-stage study with 35 participants, and the results may not apply to everyone. The treatments can cause temporary redness, swelling, or other side effects, and the preventive benefit against skin cancer is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Clinical signs of facial photodamage, including low-grade actinic keratosis (Olsen grade I-II) , solar lentigines, mottled hyper- and hypopigmentation, telangiectasia, skin thinning or atrophy, loss of skin elasticity (solar elastosis), coarse, leathery texture Exclusion Criteria: * Fitzpatrick skin type ≥ 4 * Active skin disease in the treatment area that may interfere with study treatment or assessments * Cosmetic treatments in the face within the last 12 months, including but not limited to chemical peels, injectables, and light- or laser-based treatments * Pregnancy or breastfeeding * Contraindications to the three lasers or topical anesthetics * Fitzpatrick skin type ≥ 4 * Active skin disease in the treatment area that may interfere with study treatment or assessments * Cosmetic treatments in the face within the last 12 months, including but not limited to chemical peels, injectables, and light- or laser-based treatments * Pregnancy or breastfeeding * Contraindications to the three lasers or topical anesthetics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Actinic keratosis (AK) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

actinic keratosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Actinic keratosis (AK) Photo-damage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Dermatology, Bispebjerg Hospital

    RECRUITING

    Copenhagen NV, 2400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.